Show simple item record

 
dc.contributorDepartament de Salut
dc.date.accessioned2019-03-27T13:32:52Z
dc.date.available2019-03-27T13:32:52Z
dc.date.issued2018-09-26
dc.identifier.citationPropiverina per al tractament dels símptomes urinaris en la síndrome de bufeta hiperactiva. Barcelona: Servei Català de la Salut; 2018.
dc.identifier.urihttp://hdl.handle.net/11351/3878
dc.descriptionPropiverina; Hyperactive bladder syndrome; Urinary symptoms:
dc.description.abstractHyperactive bladder syndrome (SBH) is characterized by urinary urge, with urinary incontinence (UU) of urgency or without, with absence of infection or of another obvious pathology, and that is usually associated with an increase in daytime urinary frequency and nocturia. Urgency is the distinctive symptom of SBH and it is defined as a sudden and imperative urge to urinate the urination.
dc.language.isocat
dc.publisherServei Català de la Salut
dc.relation.ispartofPrograma d'harmonització farmacoteràpeutica, Servei Català de la Salut
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectBufeta - Malalties
dc.subjectAntiespasmòdics - Ús terapèutic
dc.subjectMedicaments - Assaigs clínics
dc.subject.meshParasympatholytics
dc.subject.mesh/drug therapy
dc.subject.meshDrug Evaluation
dc.subject.meshUrinary Bladder, Overactive
dc.titlePropiverina per al tractament dels símptomes urinaris en la síndrome de bufeta hiperactiva
dc.typeinfo:eu-repo/semantics/report
dc.subject.decsparasimpaticolíticos
dc.subject.decs/uso terapéutico
dc.subject.decsevaluación de medicamentos
dc.subject.decsvejiga urinaria hiperactiva
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record